These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30907011)

  • 21. Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.
    Jain N; Singh S; Laliotis G; Hart A; Muhowski E; Kupcova K; Chrbolkova T; Khashab T; Chowdhury SM; Sircar A; Shirazi F; Singh RK; Alinari L; Zhu J; Havranek O; Tsichlis P; Woyach J; Baiocchi R; Samaniego F; Sehgal L
    Blood Adv; 2020 Sep; 4(18):4382-4392. PubMed ID: 32926124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD79B limits response of diffuse large B cell lymphoma to ibrutinib.
    Kim JH; Kim WS; Ryu K; Kim SJ; Park C
    Leuk Lymphoma; 2016; 57(6):1413-22. PubMed ID: 26699656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.
    Kuo HP; Ezell SA; Hsieh S; Schweighofer KJ; Cheung LW; Wu S; Apatira M; Sirisawad M; Eckert K; Liang Y; Hsu J; Chen CT; Beaupre D; Chang BY
    Am J Cancer Res; 2016; 6(11):2489-2501. PubMed ID: 27904766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma.
    Zhao Y; Yang J; Liu J; Cai Y; Han Y; Hu S; Ren S; Zhou X; Wang X
    Cell Death Dis; 2021 Jun; 12(7):640. PubMed ID: 34162828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.
    Ezell SA; Mayo M; Bihani T; Tepsuporn S; Wang S; Passino M; Grosskurth SE; Collins M; Parmentier J; Reimer C; Byth KF
    Oncotarget; 2014 Jul; 5(13):4990-5001. PubMed ID: 24970801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.
    Li J; Qian C; Zhou Q; Li J; Li K; Yi P
    Biochem Biophys Res Commun; 2017 Sep; 491(4):939-945. PubMed ID: 28756223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.
    Ma J; Lu P; Guo A; Cheng S; Zong H; Martin P; Coleman M; Wang YL
    Br J Haematol; 2014 Sep; 166(6):849-61. PubMed ID: 24957109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.
    Jin J; Wang L; Tao Z; Zhang J; Lv F; Cao J; Hu X
    Mol Med Rep; 2020 May; 21(5):2209-2219. PubMed ID: 32186759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
    Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
    PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells.
    Kim SW; Oleksyn DW; Rossi RM; Jordan CT; Sanz I; Chen L; Zhao J
    Blood; 2008 Feb; 111(3):1644-53. PubMed ID: 18025152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.
    Derenzini E; Agostinelli C; Imbrogno E; Iacobucci I; Casadei B; Brighenti E; Righi S; Fuligni F; Ghelli Luserna Di Rorà A; Ferrari A; Martinelli G; Pileri S; Zinzani PL
    Oncotarget; 2015 Mar; 6(9):6553-69. PubMed ID: 25544753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis.
    Guan S; Lu J; Zhao Y; Woodfield SE; Zhang H; Xu X; Yu Y; Zhao J; Bieerkehazhi S; Liang H; Yang J; Zhang F; Sun S
    Oncotarget; 2017 May; 8(20):33666-33675. PubMed ID: 28430599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
    Tanaka H; Kaneko N; Sakagami H; Matsuya T; Hiramoto M; Yamanaka Y; Mori M; Koshio H; Hirano M; Takeuchi M
    Leuk Res; 2020 Jan; 88():106286. PubMed ID: 31865062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.
    Gaudio E; Tarantelli C; Kwee I; Barassi C; Bernasconi E; Rinaldi A; Ponzoni M; Cascione L; Targa A; Stathis A; Goodstal S; Zucca E; Bertoni F
    Ann Oncol; 2016 Jun; 27(6):1123-1128. PubMed ID: 26961147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.
    Chen Y; Bai G; Ning Y; Cai S; Zhang T; Song P; Zhou J; Duan W; Ding J; Xie H; Zhang H
    Eur J Med Chem; 2020 Mar; 190():112092. PubMed ID: 32014679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.
    Li J; Huang Y; Zhang Y; Wen J; Chen Y; Wang L; Jiang P; Hu J
    Med Oncol; 2021 Feb; 38(4):33. PubMed ID: 33629212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14.
    Choi J; Phelan JD; Wright GW; Häupl B; Huang DW; Shaffer AL; Young RM; Wang Z; Zhao H; Yu X; Oellerich T; Staudt LM
    Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6092-6102. PubMed ID: 32127472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.
    Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Mason NJ
    Clin Cancer Res; 2011 Jul; 17(14):4661-71. PubMed ID: 21610150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.
    Stewart CM; Michaud L; Whiting K; Nakajima R; Nichols C; De Frank S; Hamlin PA; Matasar MJ; Gerecitano JF; Drullinsky P; Hamilton A; Straus D; Horwitz SM; Kumar A; Moskowitz CH; Moskowitz A; Zelenetz AD; Rademaker J; Salles G; Seshan V; Schöder H; Younes A; Tsui DWY; Batlevi CL
    Clin Cancer Res; 2022 Jan; 28(1):45-56. PubMed ID: 34615723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.
    Spriano F; Tarantelli C; Gaudio E; Gerlach MM; Priebe V; Cascione L; Bernasconi E; Targa A; Mascia M; Dirnhofer S; Stathis A; Zucca E; Bertoni F
    Br J Haematol; 2019 Dec; 187(5):595-601. PubMed ID: 31355927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.